Evaluation of the effectiveness of prolotherapy on patients with knee osteoarthritis

comparison of intra articular prolotherapy versus peri articular prolotherapy on decreasing pain and improvement of the function in patient with knee osteoarthritis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016091229795N1

Enrollment

Registered

2016-10-30

Start date

2016-04-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: arthrosis of knee. Condition 2: arthrosis of knee. Primary gonarthrosis, bilateral Other primary gonarthrosis

Interventions

Intervention 1: in first group patient lies at bed, patient’s knee with placing a pillow under it flexes to 30 degrees then practitioner prep the knee and injects 5 cc dextrose 25% from inferiolatera

Treatment - Drugs

in first group patient lies at bed, patient’s knee with placing a pillow under it flexes to 30 degrees then practitioner prep the knee and injects 5 cc dextrose 25% from inferiolateral side of the k

In second group injects 5cc dextrose 25 % by using 25 gauge syringe around knee joint maximum in two points (lateral or medial) that is the most painful, except pesanserine bursitis. Preparation of d

Eligibility

Sex/Gender

All

Age

38 Years to 75 Years

Inclusion criteria

Inclusion criteria: inclusion croteria: patient had these symptoms atleast for 1 month joint stiffness; criptation; knee pain. exclusion criteria: any intra or extra knee jonit injection in past 3 months; total knee arthroplasty; lumbo sacral radiculopathy; uncontrolled diabetic mellitus with HbA1C more than7.5; reumatic disorders such as rheumatoid arthritis,goat, SLE, brucella; knee truma during 3 months ago; knee fracture during 3 months ago; BMI more than 42.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: befor injection, 2 and 4 weeks after injection. Method of measurement: Visual Analog Scale( VAS).;Patient function. Timepoint: befor injection and 2 and 4 weeks after injection. Method of measurement: The WOMAC consists of 24 items divided into 3 subscales:Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing.Stiffness (2 items): after first waking and later in the day.Physical Function (17 items): stair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties.	—

Measure

Time frame

Pain. Timepoint: befor injection, 2 and 4 weeks after injection. Method of measurement: Visual Analog Scale( VAS).;Patient function. Timepoint: befor injection and 2 and 4 weeks after injection. Method of measurement: The WOMAC consists of 24 items divided into 3 subscales:Pain (5 items): during walking, using stairs, in bed, sitting or lying, and standing.Stiffness (2 items): after first waking and later in the day.Physical Function (17 items): stair use, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on / taking off socks, rising from bed, lying in bed, getting in / out of bath, sitting, getting on / off toilet, heavy household duties, light household duties.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereydooni Farzane

Department of Physical Medicine and Rehabilitation

fereydooni.farzane@yahoo.com+98 71 3231 9040

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 8, 2026